IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

Ashby et al

SERIAL NO.:

09/621,670

FILING DATE:

7/24/00

TITLE:

Depth And Puncture Control For System For Hemostasis Of Blood

Vessel

EXAMINER:

Izaguirre, Ismael

ART UNIT:

3765

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Rostal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date printed below:

Date: N

May U, 2004

Name

Ruth Rodriquez

COMMISSIONER FOR PATENTS P.O. Box 1450, ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Each item of information listed in the attached FORM PTO-1449, for which a copy of each is attached (unless the blanket waiver referred to below applies), may be material to the examination of the above-identified application and is, therefore, submitted in compliance with the duty of disclosure defined in 37 CFR §§ 1.56, 1.97 and 1.98. The Examiner is requested to review, consider and document each such item in the official record of this application.

Note: If this box is checked, this case was filed after June 30, 2003 and qualifies for the blanket waiver of deposit of copies of U.S. Patents and U.S. Patent Application

Publications in accordance with the written waiver of 37 CFR §1.98 (a)(2)(i) dated July 11, 2003. Accordingly, such copies are not attached.

This Information Disclosure Statement under 37 CFR §§ 1.56, 1.97 and 1.98 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these items constitutes prior art.

I

This statement is filed pursuant to (CHECK ONE BOX):

X 37 C.F.R. § 1.97(b). This information disclosure statement is filed either: (1) within three months of the filing date of a national application other than a continued prosecution application under §1.53(d); (2) within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; (3) before the mailing date of a first office action on the merits; or (4) before the mailing of a first office action after the filing of a Request for Continued Examination under 37 C.F.R. §1.114, whichever event occurs last. Accordingly, this information disclosure statement requires no fee and no certification. 37 C.F.R. § 1.97(c). This information disclosure statement is filed after the period specified in 37 C.F.R. § 1.97(b), but before the mailing date of any of the following: (1) a final action under 37 C.F.R. § 1.113; (2) a notice of allowance under 37 C.F.R. § 1.311; or (3) an action that otherwise closes prosecution in the application.

Accordingly, this information disclosure statement requires either:

- (1) the fee specified in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under 37 C.F.R. § 1.97(c); or
 - (2) a certification according to 37 C.F.R. § 1.97 (e)(1) or (2).

37 C.F.R. § 1.97(d).

This information disclosure statement is filed after the period specified in 37 C.F.R.. § 1.97 (c).

Accordingly, this information disclosure statement requires:

- (1) a certification in accordance with 37 C.F.R. § 1.97(e); and
- (2) the fee specified in 37 C.F.R. § 1.17 (p) to consider an information disclosure statement under 37 C.F.R. § 1.97(d).

If this statement crosses in the mail with an office action, or is otherwise not in the indicated category of 37 C.F.R. § 1.97, it is respectfully requested that this statement be treated in the next appropriate category and made of record. To the extent required, please treat this paper as a conditional petition for acceptance of the information disclosure statement.

II Fees Due (CHECK ONE BOX): No fee is due. The fee specified in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under 37 C.F.R. § 1.97(c) or 37 C.F.R. § 1.97(d) is enclosed (\$180). Ш Certification (CHECK ONE BOX): M No certification is necessary. Pursuant to 37 C.F.R. § 1.97(e)(1), the undersigned hereby certifies: That each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement. Pursuant to 37 C.F.R. § 1.97(e)(2), the undersigned hereby certifies: No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in

this information disclosure statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this information disclosure statement.

IV

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Please charge any additional required fee or credit any overpayment to our deposit account number 50-1698.

Respectfully submitted,

THELEN REID & PRIEST LLP

Dated: May / 10, 2004

Adrienne Yeung

Reg. No. 44,000

THELEN REID & PRIEST LLP P.O. Box 640640 San Jose, CA 95164-0640 (408) 292-5800 direct dial (408) 287-8040 direct fax MAY 2 1 2004 3

SUB-Q 1449 US

1015

Form PTO 1449
(Rev. 2-32)
U.S. Department of Commerce
Patent and Trademark Office

Information Disclosure Statement by Applicant

(Use several sheets if necessary)

Atty. Docket No.
034298-068

Applicant: Ashby et al

Filed: 7/24/00

Group: 3765

U.S. Patent Documents

Init.		Document No.	Date	Name	Class	Subclass	Date
	A	2,370,319		J.G. Lippinott			7/1937
	В	2,874,776		H.E. Hooe			2/59
	С	3,358,689		John L. Higgins			12/19/67
	D	3,411,505		P.D. Nobis			11/19/68
	Е	3,736,939		Glenn N. Taylor			6/5/73
-	F	4,573,573		Thomas C. Krol			3/86
	G	4,644,649		Seaman et al			2/87
-	Н	4,852,568		Kensey			8/89
	I	4,573,576		Thomas C. Krol	٠		3/83
	J	4,869,143		Merrick			9/89
	K	4,098,728		Solomon Rosenblatt			7/4/78
	L	4,219,026		Terry No. Layton			8/26/80
	M	4,224,945		Jonathan Cohen			9/30/80
	N	4,405,314		Constantin Copi			9/20/83
	0	4,699,616		George M. Norwak			10/13/87
	P	4,832,688		Sagae, et al			5/23/89
	Q	4,839,204		Yoshino ·	100		6/13/89
	R	5,399,361		Song, et al			3/95
	S	5,462,194		Keith Barawell			10/95
	T	5,385,550		Su, et al.			1/95
	U	5,800,389		Burney et al.		- 1011	9/98
	V	5,507,279		Fortune			4/96
	W	5,858,008	-	Capaccio			1/99
	X	5,049,138		Chevalier et al			9/17/91
	Y	5,129,889		John L. Hahn			7/14/92
	Z	5,192,290		Said Hilgal			3/9/93
	A1	5,219,899		Panster et al			6/15/93
	B1	5,232,453		Plass et al			8/3/93
	Cl	5,254,105		John Haaga			10/19/93
	D1	5,320,639		James Rudnick			6/14/94
	El	5,342,388		Sonia Toller			8/30/94
	F1	5,350,399		Erlebacher et al			9/27/94

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

Init.		Document No.	Date	Name	Class	Subclass	Date
	G1	5,352,211		William Merskelly	-		10/4/94
	H1	5,447,502		John Haaga			9/5/95
		5,458,570		James May, Jr			10/17/95
	J1	5,545,175		Abidin et al			8/13/96
	K1	5,571,168		Connie Toro			11/5/96
•	L1	5,601,601		Tal et al			2/11/97
· ·	M1	5,620,461		Wouter M. Muijs Van De Moer			4/15/97
	N1	5,674,346		Nikhil K. Kundel			10/7/97
	01	5,707,393		Kensey et al			1/13/98
_	P1	5,931,165		Reich et al			8/3/99
	Q1	6,027,471		Fallon et al.			2/00
	R1	6,027,482		Imbert			2/00
	S1	6,086,607	<u> </u>	Cragg et al.			7/00
	T1	6,161,034	 	Burbank et al.			12/00
	U1	6,183,497		Sing et al.			2/01
	V1	6,033,427		Benjamin Lee			3/7/00
	W1	6,056,768		Cates et al			5/2/00
	X1	6,066,325		Wallace et al			5/23/00
	Y1	6,090,130		Nash et al			7/18/00
	Z1	6,126,675		Shchervinsky et al			10/3/00
	A2	6,371,974	9	Brenneman et al		17 1	4/02
	B2	6,440,151		Cragg et al		-	8/02
	C2	6,440,153		Cragg et al			8/02
·	D2	6,477,534		Cragg et al			\$/02
	E2	6,503,222		Julian Lo			1/03
	F2	6,527,734		Cragg et al			3/03
	G2	6,540,735		Ashby et al			4/03
	H2	6,544,236		Cragg et al			4/03
	I2	6,610,026		Cragg et al			8/03
	J2	US2002/000288 9		Ashby et al			1/10/02
	K2	US2002/001661 2		Ashby et al			2/7/02

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

Date Considered

Examiner

U.S. Department of Commerce Patent and Trademark Office Form PTO 1449 Atty. Docket No. Serial No. 034298-068 09/621,670 (Rev. '2-32) Applicant: Ashby et al Information Disclosure Statement by Applicant Filed: 7/24/00 Group: 3765 (Use several sheets if necessary) **U.S. Patent Documents** Class Subclass Date Document No. Date Name Init. 3/28/02 L2 US2002/003813 Chi Sing et al 4/11/02 M2 US2002/004237 Reich et al 5/23/02 N2 US2002/006210 Ashby et al 10/24/02 O2 US2002/015649 Brenneman et al 2/6/03 US2003/002814 Greff et al P2 Q2 US2003/008826 Mark Ashby 5/8/03 5/8/03 R2 US2003/008827 Cragg et al S2 US2003/012025 Ashby et al 6/26/03 8 T2 US2003/013523 Cragg et al 7/17/03 US2004/001932 1/29/04 U2 Chi Sing et al 1/29/04 V2 US2004/001933 Mark Ashby 0 Date Considered Examiner

MAY 2 1 2004 3

SUB-Q 1449 FOREIGN

40f 5

Form PTO 1449	Atty. Docket No.	Serial No.
(Rev. 2-32) U.S. Department of Commerce	034298-068	09/621,670
Patent and Trademark Office		
	Applicant: Ashby et a	ıl
Information Disclosure Statement by Applicant		
	Filed: 7/24/00	Group: 3765
(Use several sheets if necessary)		

Foreign Documents

							Tra	nslatio
Init.		Document No.	Date	Country	Class	Subclass	Yes	No
	W2	0637432 B1**		EP				
	X2	2641692**	07/90	France				10
	Y2	WO 97/07934**		PCT			X	
				-				
•	-		*				1	
							1	
								†
							-	
								
							+	 -
				-				1
						·-		
						<u> </u>		
				_				
								ļ
	_							ļ
							-	-
			<u> </u>			_		-
			_				-	
								-
								ļ
				A C				<u> </u>
						<u> </u>		



Form PTO 144 (Rev. 2-32)	U.S. Department of Commerce	Atty. Docket No. 034298-068	Serial No. 09/621,670				
	Patent and Trademark Office						
Info	ormation Disclosure Statement by Applicant	Applicant: Ashby et	al				
	(Use several sheets if necessary)	Filed: 7/24/00	Group: 3765				
Z2	Berman, et al "Guided Direct Antegrade Puncture 0361-803X/86/1473-0632 © American Roentgen	-	rtery" AJR 147:632-634, 9/8				
A3	Berman et al "Modification of the Cope Drainage 0361-803X/86/1461-0169 © American Ray Socie	ty					
B3	Correll, John T. et al. Biologic investigations of n	ew absorbable sponge; pg 585	5				
. C3	Di Seni, Ricardo, et al, "Part 1, Embolotherapy: Agents pgs 29 & 33						
- D3	Saddekni, MD et al "Antegrade Catheterization of 532						
• E3	Vogelzang "A Modified Cope Introducing Dilator to Allow Straight Guide Wire Introduction" AJR 146:381 382 2/86 0361-803X/86/1462-0381 © American Roentgen Ray Society						
F3	Our Pending Applications						
G3	Ashby, Mark et al; Serial No. 10/287,922; filed: No. 10/287,922; fil	Nov. 4, 2002; entitled: Appara	tus And Method For				
H3	Ashby, Mark et al; Serial No. 10/069,107; filed: Dec. 1 Of An Incision						
13	Ashby, Mark et al; Serial No. 10/278,710; filed: Oct. 2 of Blood Vessel Punctures With Absorbable Sponge						
J3	Ashby, Mark et al; Serial No. 10/334,770; filed: Dec 3 Hemostasis with Absorbable Sponge						
K3	Ashby, Mark et al; Serial No. 10/421,680; filed Apr. 2. Technique						
L3 M3	Ashby, Mark et al; Serial No. 10/462,065; filed: Jun. 12, 2003; entitled: Enhanced Bleed Back System Ashby, Mark et al, Serial No. 10/462,064; filed: Jun. 12, 2003; entitled: Release Mechanism						
N3	Ashby, Mark et al; Serial No. 10/461,587; filed: Jun. 12, 2003; entitled: Dissolvable Closure Device						
O3	Ashby, Mark et al; Serial No. 10/461,035; filed: Jun. 13, 2003; entitled: System And Method For Delivering Hemostasi Promoting Material To A Blood Vessel Puncture Site Using a Cannua						
Р3	Ashby, Mark et al; Serial No. 10/461,006; filed: Jun. 1 Promoting Material to a Blood Vessel Puncture with a	3, 2003, entitled: System and Me	ethod for Delivering Hemostasi				
Q3	Ashby, Mark et al; Serial No. 10/460,859; filed: Jun. 1	2, 2003; entitled: Hemostatic De	vice Including a Capsule				
R3	9, 2003; entitled: Pledget-Handlin Vessel Puncture Site By Fluid Pro	essure					
S3	Ashby, Mark et al; Serial No. 10/754,824; filed: Jan. 9	, 2004; entitled: Sheath-Mounted	Arterial Plug Delivery Device				
Examiner		Date Consid	lered				

if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

SV #166727 v1